Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms

Inflammatory bowel diseases, comprising Crohn’s disease (CD) and ulcerative colitis (UC), are chronic, relapsing and remitting immune-mediated inflammatory diseases affecting the gastrointestinal tract. Vedolizumab is the first licensed drug in a group of ‘gut-selective’ biological agents used to tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Crooks, Benjamin, Barnes, Tom, Limdi, Jimmy K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055512/
https://www.ncbi.nlm.nih.gov/pubmed/32180822
http://dx.doi.org/10.7573/dic.2019-10-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055512/
https://www.ncbi.nlm.nih.gov/pubmed/32180822
http://dx.doi.org/10.7573/dic.2019-10-2

Ejemplares similares